WO2022268916A2 - Pan-coronavirus peptide vaccine - Google Patents
Pan-coronavirus peptide vaccine Download PDFInfo
- Publication number
- WO2022268916A2 WO2022268916A2 PCT/EP2022/067082 EP2022067082W WO2022268916A2 WO 2022268916 A2 WO2022268916 A2 WO 2022268916A2 EP 2022067082 W EP2022067082 W EP 2022067082W WO 2022268916 A2 WO2022268916 A2 WO 2022268916A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine composition
- seq
- ctl
- epitopes
- nos
- Prior art date
Links
- 229940023041 peptide vaccine Drugs 0.000 title description 3
- 229960005486 vaccine Drugs 0.000 claims abstract description 126
- 239000000203 mixture Substances 0.000 claims abstract description 125
- 241000008904 Betacoronavirus Species 0.000 claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 241000004176 Alphacoronavirus Species 0.000 claims abstract description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 113
- 108020004707 nucleic acids Proteins 0.000 claims description 113
- 150000007523 nucleic acids Chemical class 0.000 claims description 109
- 108020004999 messenger RNA Proteins 0.000 claims description 25
- 150000002632 lipids Chemical class 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 15
- 241001678559 COVID-19 virus Species 0.000 claims description 13
- 241000315672 SARS coronavirus Species 0.000 claims description 12
- -1 amino lipid Chemical class 0.000 claims description 12
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 235000010446 mineral oil Nutrition 0.000 claims description 7
- 239000002480 mineral oil Substances 0.000 claims description 7
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 5
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- BGNVBNJYBVCBJH-UHFFFAOYSA-N SM-102 Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCC(OCCCCCCCCCCC)=O BGNVBNJYBVCBJH-UHFFFAOYSA-N 0.000 claims description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 238000007385 chemical modification Methods 0.000 claims 2
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 abstract description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 98
- 108090000765 processed proteins & peptides Proteins 0.000 description 68
- 210000001744 T-lymphocyte Anatomy 0.000 description 42
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 17
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 13
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 13
- 210000002443 helper t lymphocyte Anatomy 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 229940042472 mineral oil Drugs 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 4
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 3
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 102000016397 Methyltransferase Human genes 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 229930185560 Pseudouridine Natural products 0.000 description 3
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101150106931 IFNG gene Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- FHHZHGZBHYYWTG-INFSMZHSSA-N [(2r,3s,4r,5r)-5-(2-amino-7-methyl-6-oxo-3h-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate Chemical compound N1C(N)=NC(=O)C2=C1[N+]([C@H]1[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O1)O)=CN2C FHHZHGZBHYYWTG-INFSMZHSSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- XLKQWAMTMYIQMG-SVUPRYTISA-N (2-{[(2r)-2,3-bis[(4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC XLKQWAMTMYIQMG-SVUPRYTISA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- SSCDRSKJTAQNNB-DWEQTYCFSA-N 1,2-di-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC SSCDRSKJTAQNNB-DWEQTYCFSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- PDXQSLIBLQMPJS-FDDDBJFASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methoxymethyl)pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(COC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 PDXQSLIBLQMPJS-FDDDBJFASA-N 0.000 description 1
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 1
- CZINFFCCOSHTMZ-NYVOMTAGSA-N 2-[bis[(Z)-octadec-9-enoyl]amino]ethyl [(2R)-2,3-dihydroxypropyl] hydrogen phosphate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCC\C=C/CCCCCCCC)=O CZINFFCCOSHTMZ-NYVOMTAGSA-N 0.000 description 1
- SLQKYSPHBZMASJ-QKPORZECSA-N 24-methylene-cholest-8-en-3β-ol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@H]21 SLQKYSPHBZMASJ-QKPORZECSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- IZFJAICCKKWWNM-JXOAFFINSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methoxypyrimidin-2-one Chemical compound O=C1N=C(N)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IZFJAICCKKWWNM-JXOAFFINSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- AMMRPAYSYYGRKP-BGZDPUMWSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-ethylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(CC)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 AMMRPAYSYYGRKP-BGZDPUMWSA-N 0.000 description 1
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000755093 Gaidropsarus vulgaris Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 description 1
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 1
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100030991 Nucleolar and spindle-associated protein 1 Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- WIHSZOXPODIZSW-KJIWEYRQSA-N PE(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)) Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC WIHSZOXPODIZSW-KJIWEYRQSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020005073 RNA Cap Analogs Proteins 0.000 description 1
- 101710200092 Replicase polyprotein Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- XYNPYHXGMWJBLV-VXPJTDKGSA-N Tomatidine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@@]11CC[C@H](C)CN1 XYNPYHXGMWJBLV-VXPJTDKGSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- SUTHKQVOHCMCCF-QZNUWAOFSA-N [(2r)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-docosa-2,4,6,8,10,12-hexaenoyloxypropyl] docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)C=CC=CC=CC=CC=CC=CCCCCCCCCC SUTHKQVOHCMCCF-QZNUWAOFSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SLQKYSPHBZMASJ-UHFFFAOYSA-N bastadin-1 Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(C)CCC(=C)C(C)C)CCC21 SLQKYSPHBZMASJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 150000001985 dialkylglycerols Chemical class 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- PWRIIDWSQYQFQD-UHFFFAOYSA-N sisunine Natural products CC1CCC2(NC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OC(CO)C(O)C(O)C9OC%10OC(CO)C(O)C(O)C%10O)C8O)C(O)C7O PWRIIDWSQYQFQD-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- XYNPYHXGMWJBLV-OFMODGJOSA-N tomatidine Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@]6(O[C@H]5C4)NC[C@@H](C)CC6)CC3)CC2)CC1 XYNPYHXGMWJBLV-OFMODGJOSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108010027510 vaccinia virus capping enzyme Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to the field of the medicine, especially of virology. More particularly, it relates to a vaccine against coronavirus.
- Betacoronaviruses have become of the greatest clinical importance as illustrated by COVID-19 pandemic caused by SARS-CoV-2. All viruses, including SARS-CoV-2, evolve over time and variants of the original virus appear. Thus, a vaccine designed to target the original virus could be less effective against some of the variants. Another issue is that SARS-CoV-2 is not the first Betacoronavirus that causes an epidemic. Indeed, SARS-CoV-1 was responsible of an epidemic in 2003 and the MERS-CoV was responsible of an epidemic in 2012. It is likely that other Betacoronaviruses emerge in the future. Therefore, one problem to solve is to provide a vaccine as universal as possible so as to be effective against the new variants or coronaviruses that could emerge.
- Betacoronavirus includes four subgenera or lineages (A, B, C and D). OC43 and HKU1 cause the common cold and belong to lineage A; SARS-CoV-1 causing SARS and SARS-CoV-2 causing COVID-19 belong to lineage B and MERS-CoV causing MERS belongs to lineage C. Until now, epidemic and pandemic were caused by Betacoronaviruses. However, Alphacoronaviruses 229E and NL63 also cause common cold. Therefore, a vaccine against all human coronaviruses, either alpha or beta, could be advantageous.
- Vaccines against coronavirus often target spike (S) proteins, sometimes the Nucleocapsid (N) proteins, which are both exposed at the surface of the virus.
- S spike
- N Nucleocapsid
- the inventors had an approach based on mid and long term resistance against variants of the virus, instead of main action and/or recognition mechanism (mainly spike, nucleocapsid, membrane, envelope proteins) and concluded notably that the Spike, Nucleocapsid and Envelopetargets are not appropriate for a long-term and broad Betacoronavirus protection based on T- cell immunity.
- main action and/or recognition mechanism mainly spike, nucleocapsid, membrane, envelope proteins
- T-cell epitopes are well conserved among the human Betacoronaviruses. 21 of them are located in the ORFlab replicase polyprotein and only one in the Membrane protein (see Tables 1 and 2). More specifically, 10 T cell epitopes have been identified as having 100 % homology with at least 4 out of the 5 human betacoronaviruses (SARS-CoV-1, SARS-CoV- 2, MERS-CoV, HCoV-OC43 and HCoV-HKUl) (see Table 1).
- 6T-cell epitopes have been identified as having 100% homology with the 5 human betacoronaviruses and one of them (namely ab0o ⁇ /#1 SEQ ID NO: 1) is of particular interest because it presents 100 % homology with the two alpha and the five beta coronaviruses (betacoronaviruses SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV- OC43 and HCoV-HKUl; alphacoronaviruses 229E and NL63). 12 additional T cell epitopes with a single mismatch in the HLA-binding anchorage site and covering at least 4 out of 5 human betacoronaviruses have been identified.
- the inventors designed neo-epitopes (mutated epitopes) of some of these T cell epitopes (see Table 3) by substituting some amino acids in HLA-binding anchorage site to improve HLA affinity, hence immunogenicity and or world HLA coverage.
- Another advantage of the identified epitopes is that the epitopes have been selected also based on a large word HLA coverage ranging from 40 to 100 % in order not to be restricted to few HLA genotypes in the face of the difficulty of high HLA polymorphism in human.
- the epitopes will be recognized by CD8 T cells through the interaction with HLA class I system.
- the activated CD8 T cells convert into Lymphocytes cytotoxic T cells (effector CTL) by the help of helper T Lymphocytes (HTL).
- the activated T cells are notably CD8 memory T cells allowing the long-term action of the vaccine.
- T cell epitopes suitable for preparing a multi-epitopes vaccine being adapted to provide a protection against several betacoronaviruses and optionally alphacoronaviruses. According to our knowledge, it is the first time that the identification of T cell epitopes is focused on this capacity to provide a broad protection among the betacoronaviruses.
- Table 1 10 T cell epitopes with 100 % homology with at least 4 out of the 5 human betacoronaviruses
- Table 2 12 T-cell epitopes covering at least 4 out of 5 human betacoronaviruses with a single mismatch in the HLA-binding
- Table 3 neoepitope of some T-cell epitopes of Tables 1 and 2
- the epitopes of Tables 1-3 are stable among the SARS-Cov-2clades, and none of them are mutated in the 15 variants of SARS-Cov-2 described to this date (B.l.1.7 (Alpha), B.1.351 (Beta), P.l (Gamma), B.1.427 /429 (Epsilon), B.l.617.1 (Kappa), B.l.617.2 (Delta), A.23.1, B.1.526 (lota), C.37, B.1.525 (Eta), P.3 (Theta), B.1.1.519, B.1.619, B.1.620, B.1.621).
- the present invention relates to a vaccine composition
- a vaccine composition comprising at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 2, 5-10 and 12-32.
- the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, 4 and 11 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs 24, 25 and 28.
- the present invention relates to a vaccine composition
- a vaccine composition comprising at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 5-10 and 13-32.
- the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-4 and 11-12 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs 24, 25 and 28.
- the present invention further relates to a vaccine composition
- a vaccine composition comprising a nucleic acid or a set of nucleic acids encoding at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-32.
- the nucleic acid or set of nucleic acids encodes at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2, 5-10 and 12-32.
- the nucleic acid or set of nucleic acids further encodes at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, 4 and 11.
- pan-betacoronaviruses optionally pan-alpha and betacoronaviruses
- T cell memory CTL Cytotoxic T Lymphocytes
- the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2, 5-10 and 12-32 or nucleic acid or set of nucleic acids encoding such at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitope.
- the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, 4 and 11 or nucleic acid or set of nucleic acids encoding such at least one CTL epitope.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23 and 26 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23 and 26 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, and 4 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 24 and 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, and 4 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 24 and 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition further comprises an epitope of SEQ ID NO: 1 or a neoepitope of the epitope of SEQ ID NO: 1 such as the neoepitope of SEQ ID NO: 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 12-22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 29-32 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 12-22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 29-32 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NO: 11 or a neoepitope thereof such as the neoepitopes of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitopes selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23 and 26 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- CTL (neo)epitopes selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23 and 26 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, and 4 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 24 and 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, and 4 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 24 and 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition further comprises an epitope of SEQ ID NO: 1 or a neoepitope of the epitope of SEQ ID NO: 1 such as the neoepitope of SEQ ID NO: 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitopes selected from the group consisting of epitopes of SEQ ID NOs: 12-22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 29-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes.
- CTL (neo)epitopes selected from the group consisting of epitopes of SEQ ID NOs: 12-22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 29-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes.
- the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NO: 11 or a neoepitope thereof such as the neoepitopes of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 23-32 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope.
- the vaccine composition comprises the neoepitope of SEQ ID NO: 25 or nucleic acid or set of nucleic acids encoding it.
- the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL neoepitopes selected from the group consisting of neoepitopes of SEQ ID NOs: 23-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitope.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-22 and at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 23-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes.
- the vaccine composition comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-10 and at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 23-27 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes.
- the vaccine composition comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 11-22 and at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 28-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 1-10, 12-27 and 29-31 and the CTL epitope of SEQ ID NO: 11 or a neoepitope thereof such as the CTL neoepitope of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes.
- CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 1-10, 12-27 and 29-31 and the CTL epitope of SEQ ID NO: 11 or a neoepitope thereof such as the CTL neoepitope of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes and 1 or 2 of them are the CTL epitope of SEQ ID NO: 11 or a neoepitope thereof such as the CTL neoepitope of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises at least 5, 6, 7 or 8 CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-32 or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the vaccine composition comprises between 5 and 15 CTL (neo)epitopes as disclosed above, especially between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
- the composition further comprises at least 1 HTL (Helper T Lymphocytes) peptide/epitope or a T helper peptide or nucleic acid or set of nucleic acids encoding it.
- HTL epitopes are either natural or synthetic T cells helper peptides know in the art.
- Natural helper peptides are for instance a Natural Tetanus sequence alone or linked to another epitope, or a Plasmodium falciparum sequence alone or linked to another epitope.
- the HTL peptide may comprise a synthetic peptide such as a Pan-DR-binding epitope (e.g., a PADRE ® peptide, Epimmune Inc., San Diego, CA, described, for example, in U.S. Patent Number 5,736,142), for example, having the sequence (aKXVAAWTLKAAa with X and a respectively indicating cyclohexylalanine and d-alanine) (SEQ ID NO: 33).
- Certain pan-DR binding epitopes comprise all "L" natural amino acid residues; these molecules can be provided as peptides or in the form of nucleic acids that encode the peptide. See also, U.S. Patent Numbers 5,679,640 and 6,413,935.
- the vaccine composition may further comprise an adjuvant.
- the adjuvant is preferably an oily adjuvant, which comprises both a hydrocarbon oil and a water-in-oil emulsifier. Such adjuvants act by the so-called "deposition effect".
- the hydrocarbon oil may be paraffin oil, a vegetable oil, squalene, squalane or mineral oil, for instance.
- Suitable W/O emulsifiers may be selected from mannide mono-oleate and sorbitan mono-oleate, for instance.
- oily adjuvants examples include a mixture of mineral oil and mannide mono-oleate, more particularly a mixture of 5-20% mannide mono-oleate with 80-95% mineral oil (Montanide ® ISA 51 sold by SEPPIC) or squalene (Montanide ® ISA 720 sold by SEPPIC) and similar mixtures.
- the adjuvant is a mixture of mineral oil and mannide mono- oleate, especially Montanide ® ISA 51.
- the vaccine composition is an emulsion with a mineral oil adjuvant.
- the adjuvant used in this invention may alternatively, or in addition to the above oily adjuvants, be selected from micro- and nanoparticles, such as liposomes and microspheres, of PLG, PLA, PLGA or other natural polymers such as gelatin, collagen and chitosan.
- Other adjuvants may comprise TLR ligands, Toll like receptor ligands (TLR3 and TLR9), stimulators of IFN genes (STING) agonists, cytokines such as GM- CSF and IL2, carbohydrates, bacterial derivatives, mineral salts and immune stimulating complexes (ISCOM).
- the vaccine composition may comprise aluminum salts, such as aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate.
- aluminum salts such as aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate.
- the vaccine composition may further comprise one or more "pharmaceutically acceptable carriers".
- pharmaceutically acceptable carriers typically large, slowly metabolized macromolecules such as proteins, saccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose (Paoletti, 2001, Vaccine, 19:2118-2126), trehalose (WO 00/56365), lactose and lipid aggregates (such as oil droplets or liposomes).
- Such carriers are well known to those of ordinary skill in the art.
- the vaccine compositions contain diluents, such as water, saline, glycerol, etc.
- auxiliary substances such as wetting or emulsifying agents, pH buffering substances, and the like, may be present.
- Sterile pyrogen-free, phosphate buffered physiologic saline is a typical carrier (Gennaro, 2000, Remington: The Science and Practice of Pharmacy, 20th edition, ISBN:0683306472).
- the vaccine compositions are intended for parenteral, topical, oral, intrathecal, or local administration.
- the vaccine compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. More preferably, the vaccine composition is intended for subcutaneous administration or intramuscular administration.
- the vaccine composition is intended for nasal administration.
- each peptide or (neo)epitope of the composition is present at a concentration of 0.01 mg/ml to 1 g/ml, 0.1 mg/ml to 10 mg/ml.
- each peptide can be present at a concentration of 0.5 mg/ml.
- the vaccine composition comprises the CTL (neo)epitopes, each at a dose of between 1 and 100 pg, preferably between 5 and 50 pg. It may comprise the T helper peptide, especially PADRE, at a dose of between 1 and 100 pg, preferably between 5 and 50 pg.
- the total number of epitope peptides in the composition can be from 1 to 40, from 2 to 30 or from 3 to 20 peptides.
- the vaccine composition may further comprise other peptides than disclosed in the present invention.
- the other peptides may be non-exhaustively selected among the T cell epitopes disclosed in Syed Faraz Ahmed et al (Viruses, 12, 254, 2020), W02004/110349, W02004/092360, Grifoni et al (Cell Host and Microbe, 27, 671, 2020).
- the T cell epitopes can be included in a larger peptide of less than 15, 20, 30, 40 or 50 amino acids in length.
- the T cell epitopes can be in the form of a polypeptide in which several T cell epitopes are fused.
- the T cell epitopes can be in the form of a carrier such as a nanoparticle bearing said T cell epitopes.
- the vaccine composition may include a nucleic acid encoding said T cell epitopes.
- the vaccine composition may comprise a nucleic acid or a set of nucleic acids encoding the CTL (neo)epitopes as disclosed herein.
- Nucleic acids of the vaccine can be or can include deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a b-D-ribo configuration, a-LNA having an a-L-ribo configuration (a diastereomer of LNA), 2'-amino-LNA having a 2'-amino functionalization, and 2'-amino- a-LNA having a 2'- amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA) and/or chimeras and/or combinations thereof.
- DNAs deoxyribonucleic acids
- RNAs ribonucleic acids
- TAAs glycol nucleic acids
- PNAs peptide nucleic
- the nucleic acid or set of nucleic acids of the vaccine composition is a mRNA polynucleotide or a set of mRNA polynucleotides.
- the technology of mRNA vaccine is now well-known by the person skilled in the art. For illustrating this aspect, see WO21159130, the the disclosure thereof being incorporated herein by reference.
- the composition may comprise one nucleic acid for each (neo)epitope of the vaccine or nucleic acid encoding several of the (neo)epitopes or all of the (neo)epitopes.
- mRNA polynucleotides can contain stabilizing elements, including, but not limited to untranslated regions (UTR) at their 5 '-end (5' UTR) and/or at their 3'-end (3' UTR), in addition to other structural features, such as a 5'-cap structure or a 3'-poly(A) tail.
- mRNA polynucleotides comprise at least one modification and at least one 5' terminal cap.
- 5 '-capping of polynucleotides may be completed concomitantly during the in vitro- transcription reaction using the following chemical RNA cap analogs to generate the 5'-guanosine cap structure according to manufacturer protocols: 3'-0-Me-m7G(5')ppp(5') G [the ARC A cap];G(5')ppp(5')A; G(5')ppp(5')G; m7G(5')ppp(5')A; m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA).
- 5 '-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the "Cap 0" structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA).
- Cap 1 structure may be generated using both Vaccinia Vims Capping Enzyme and a 2'-0 methyl-transferase to generate: m7G(5')ppp(5')G-2'-0- methyl.
- Cap 2 structure may be generated from the Cap 1 structure followed by the 2'-0-methylation of the 5 '-antepenultimate nucleotide using a 2'-0 methyl- transferase.
- Cap 3 structure may be generated from the Cap 2 structure followed by the 2'-0- methylation of the 5'-preantepenultimate nucleotide using a 2'-0 methyl-transferase.
- Enzymes may be derived from a recombinant source.
- the mRNA polynucleotides may comprise modified nucleotides and nucleosides.
- modified nucleotides and nucleosides can be found, inter alia, in published US application Nos. PCT/US2012/058519; PCT/US2013/075177; PCT/US2014/058897;
- modified nucleobases in nucleic acids may comprise 1- methyl-pseudouridine (iti ⁇ y), 1 -ethyl-pseudouridine (eli[>), 5-methoxy-uridine (mo5U), 5- methyl-cytidine (m5C), and/or pseudouridine (y).
- modified nucleobases include 5- methoxymethyl uridine, 5- methylthio uridine, 1-methoxymethyl pseudouridine, 5-methyl cytidine, and/or 5-methoxy cytidine.
- the polyribonucleotide may include a combination of at least two (e.g., 2, 3, 4 or more) of any of the aforementioned modified nucleobases. More specifically, the mRNA may comprise 1 -methyl- pseudouridine (iti ⁇ y) substitutions at one or more or all uridine positions of the nucleic acid. Alternatively, the mRNA may comprise 1 -methyl-pseudouridine (iti ⁇ y) substitutions at one or more or all uridine positions of the nucleic acid and 5-methyl cytidine substitutions at one or more or all cytidine positions of the nucleic acid.
- the mRNA may comprise 1 -methyl- pseudouridine (iti ⁇ y) substitutions at one or more or all uridine positions of the nucleic acid.
- the mRNA may comprise 1 -methyl-pseudouridine (iti ⁇ y) substitutions at one or more or all uridine positions of the nucleic acid and 5-methyl cytidine substitution
- the mRNA may comprise pseudouridine (y) substitutions at one or more or all uridine positions of the nucleic acid and optionally 5-methyl cytidine substitutions at one or more or all cytidine positions of the nucleic acid.
- the 3'-poly(A) tail is typically a stretch of adenine nucleotides added to the 3 '-end of the transcribed mRNA. It can, in some instances, comprise up to about 400 adenine nucleotides.
- the mRNA polynucleotide or set of mRNA polynucleotides is/are formulated in at least one lipid nanoparticle, especially a lipid nanoparticle comprising a mixture of lipids.
- Lipid nanoparticles typically comprise ionizable cationic lipid, non-cationic lipid, sterol and PEG lipid components along with the nucleic acid cargo of interest.
- lipid nanoparticles of the disclosure can be generated using components, compositions, and methods as are generally known in the art, see for example PCT/US2016/052352; PCT/US2016/068300; PCT/US2017/037551; PCT/US2015/027400;
- PCT/US2016/047406 PCT/US2016/000129; PCT/US2016/014280; PCT/US2016/014280;
- the lipid nanoparticle comprises at least one ionizable cationic lipid, at least one non-cationic lipid/neutral lipid, at least one sterol, and/or at least one polyethylene glycol (PEG)-modified lipid.
- the non-cationic lipid can be 1,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), 1,2- dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), l,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
- DMPC 1.2-dimyristoyl-sn-gly cero- phosphocholine
- DOPC l,2-dioleoyl-sn-glycero-3-phosphocholine
- DPPC 1,2-diundecanoyl-sn-glycero-phosphocholine
- DUPC 1,2-diundecanoyl-sn-glycero-phosphocholine
- POPC 1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
- POPC palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
- OChemsPC l-oleoyl-2 cholesterylhemisuccinoyl-sn-glycero-3- phosphocholine
- C16 Lyso PC 1,2- dilinolenoyl-sn-glycero-3- phosphocholine
- DUPC 1,2-diundecanoyl-sn-glycero-phosphocholine
- the PEG modified lipid can be a PEG- modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG- modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.
- the PEG-modified lipid is DMG-PEG, PEG-c- DOMG (also referred to as PEG-DOMG), PEG-DSG and/or PEG-DPG.
- the sterol can be cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha- tocopherol, and mixtures thereof.
- the lipid mixture comprises heptadecan-9-yl 8 ((2 hydroxy ethyl) (6 oxo 6- (undecyloxy)hexyl)amino)octanoate as ionizable cationic lipid, 1,2 distearoyl sn glycero-3 phosphocholine (DSPC) as neutral lipid, cholesterol as sterol and 1- monomethoxypolyethyleneglycol-2,3- dimyristylglycerol with polyethylene glycol of average molecular weight 2000 (PEG2000 DMG) as PEG- modified lipid.
- heptadecan-9-yl 8 ((2 hydroxy ethyl) (6 oxo 6- (undecyloxy)hexyl)amino)octanoate
- DSPC 1,2 distearoyl sn glycero-3 phosphocholine
- cholesterol as sterol
- the vaccine composition may comprise an 25 pg to 250 pg dose of mRNA encoding a (neo)epitope.
- the vaccine composition may further include a pharmaceutically-acceptable excipient, inert or active.
- the excipient in the pharmaceutical composition must be "acceptable” also in the sense that it is compatible with mRNA and can be capable of stabilizing it.
- One or more excipients e.g., solubilizing agents
- a pharmaceutically acceptable excipients include, but are not limited to, biocompatible vehicles (e.g., LNPs), carriers, adjuvants, additives, and diluents to achieve a composition usable as a dosage form.
- biocompatible vehicles e.g., LNPs
- carriers e.g., colloidal silicon oxide, magnesium stearate, cellulose, and sodium lauryl sulfate.
- Additional suitable pharmaceutical excipients, as well as pharmaceutical necessities for their use, are described in Remington's Pharmaceutical Sciences.
- the vaccine composition does not include an adjuvant.
- the vaccine compositions are intended for parenteral, topical, oral, intrathecal, or local administration.
- the vaccine compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. More preferably, the vaccine composition is intended for subcutaneous administration or intramuscular administration.
- the vaccine composition is intended for nasal administration.
- the vaccine composition is to be administered once, twice or more.
- two administrations can be carried out.
- the injections can be spaced by 3 weeks or 2 weeks and will be adapted to the Immune response requested and to the medical conditions of the subject to be treated.
- the present invention relates to a vaccine composition as disclosed herein for use for preventing or treating an infection by a coronavirus; the use of a vaccine composition as disclosed herein for the manufacture of a vaccine for preventing or treating an infection by a coronavirus; and to a method for preventing or treating an infection by a coronavirus in a subject, comprising the administration of an effective amount of a vaccine composition as disclosed herein.
- the coronavirus is an alphacoronavirus or a betacoronavirus, preferably a betacoronavirus. More specifically, the vaccine composition is suitable for preventing or treating an infection by several betacoronaviruses. Optionally, the vaccine composition is suitable for preventing or treating an infection by an alphacoronavirus. In one aspect, the vaccine composition as disclosed herein is for use for preventing or treating an infection by an alphacoronavirus and a betacoronavirus. In this aspect, the vaccine composition comprises the epitope of SEQ ID NO: 1 or a neoepitope thereof such as the neoepitope of SEQ ID NO: 25.
- the betacoronavirus is selected from the group consisting of SARS-CoV-1, SARS-CoV-2, MERS- CoV, HCoV-OC43 and HCoV-HKUl, more specifically the group consisting of SARS-CoV-1, SARS-CoV-2, and MERS-CoV.
- the vaccine composition as disclosed herein is for use for preventing or treating an infection by SARS-CoV-1, SARS-CoV-2, and MERS-CoV, optionally by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-OC43 and HCoV-HKUl.
- the subject to be treated is a subject aged 65 years or older, a subject having a cancer or having had a cancer, a subject being obese (In particular with severe obesity (body mass index [BMI] of 40 or higher [CDC- HCSP BMI >30]), a subject being diabetic, a subject having a hypertension, a subject having a sarcoidosis, a subject being immunocompromised, a subject who lives in a nursing home or long-term care facility, a subject with chronic lung disease or moderate to severe asthma, lung fibrosis, a subject who has serious heart conditions, a subject with chronic kidney disease undergoing dialysis and/or a subject with liver diseases; and/or a subject being HLA-A2.
- Many conditions can cause a person to be immunocompromised (including cancer treatment, smoking, bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV or AIDS, prolonged use of corticosteroids and other immune weakening medications).
- the patient could be selected on HLA typing.
- the subject is HLA-A2.
- a "diluent” includes sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred diluent for pharmaceutical compositions. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as diluents, particularly for injectable solutions.
- an “epitope” is the collective features of a molecule, such as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an immunoglobulin, T cell receptor or HLA molecule.
- an epitope can be defined as a set of amino acid residues which is involved in recognition by a particular immunoglobulin, or in the context of T cells, those residues necessary for recognition by T cell receptor proteins and/or Major Histocompatibility Complex (MHC) receptors. It is referred as "T cell epitope” and "CTL epitope”. Epitopes are present in nature, and can be isolated, purified or otherwise prepared or derived by humans.
- epitopes can be prepared by isolation from a natural source, or they can be synthesized in accordance with standard protocols in the art.
- Synthetic epitopes can comprise artificial amino acid residues, "amino acid mimetics,” such as D isomers of naturally-occurring L amino acid residues or non-naturally-occurring amino acid residues such as cyclohexylalanine.
- amino acid mimetics such as D isomers of naturally-occurring L amino acid residues or non-naturally-occurring amino acid residues such as cyclohexylalanine.
- epitopes may be referred to in some cases as peptides or peptide epitopes.
- HLA Human Leukocyte Antigen
- MHC Major Histocompatibility Complex
- HLA supertype or HLA family describes sets of HLA molecules grouped on the basis of shared peptide-binding specificities. HLA class I molecules that share somewhat similar binding affinity for peptides bearing certain amino acid motifs are grouped into such HLA supertypes.
- HLA superfamily, HLA supertype family, HLA family, and HLAxx-like molecules are synonyms.
- MHC Major Histocompatibility Complex
- HLA human leukocyte antigen
- a “native” or a “wild type” sequence refers to a sequence found in nature. Such a sequence may comprise a longer sequence in nature.
- peptide epitope and peptide epitope are used interchangeably with “oligopeptide” in the present specification to designate a series of residues, typically L-amino acid residues, connected one to the other, typically by peptide bonds between the a-amino and carboxyl groups of adjacent amino acid residues.
- a "peptide”, “epitope” and “peptide epitope” defined by a SEQ ID NO can consist in the particular SEQ ID NO and can also refer to a peptide consisting in the particular SEQ ID NO but including 1 or 2 additional amino acids at the N and/or C terminal end of the SEQ ID NO.
- one or several "peptide”, "epitope” and “peptide epitope” can be fused together in a same polypeptide.
- a “neoepitope” is a peptide or an epitope comprising one or two substitutions of an amino acid aiming to improve the HLA binding, in particular the binding by HLA-A2.
- the neoepitope only includes on substitution.
- the substituted amino acid is the C-terminal amino acid of the T cell epitope.
- a “PanDR binding” peptide, a “PanDR binding epitope,” or “PADRE ® " peptide is a member of a family of molecules that binds more than one HLA class II DR molecule.
- the pattern that defines the PADRE ® family of molecules can be referred to as an HLA Class II supermotif.
- a PADRE ® molecule binds to HLA-DR molecules and stimulates in vitro and in vivo human helper T lymphocyte (HTL) responses.
- HTL human helper T lymphocyte
- “Pharmaceutically acceptable” refers to a generally non-toxic, inert, and/or physiologically compatible composition or component of a composition.
- a “pharmaceutical excipient” or “excipient” comprises a material such as an adjuvant, a carrier, pH- adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like.
- a “pharmaceutical excipient” is an excipient which is pharmaceutically acceptable.
- infection by a coronavirus designates any infection or disease caused by the coronavirus.
- a “protective immune response” or “therapeutic immune response” refers to a CTL and/or an HTL response to an antigen derived from a pathogenic antigen (e.g., an antigen from an infectious agent or a tumor antigen), which in some way prevents or at least partially arrests disease symptoms, side effects or progression.
- the immune response may also include an antibody response which has been facilitated by the stimulation of helper T cells.
- a "vaccine” is a composition used for vaccination, e.g., for prophylaxis or therapy, that comprises one or more peptides of the invention.
- vaccines in accordance with the invention, such as by a cocktail of one or more peptides; one or more peptides of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide.
- the "one or more peptides” can include any whole unit integer from 1-32, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 peptides of the invention.
- the peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences.
- HLA class l-binding peptides of the invention can be linked or to otherwise be combined with HLA class II- binding peptides, e.g., a PADRE ® universal HTL-binding peptide, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes.
- Vaccines can comprise peptide pulsed antigen presenting cells, e.g., dendritic cells.
- pan coronavirus peptides to HLA expressed on the cell surface is to be measured using a T2 binding assay wild type peptides and optimized peptides will be compared.
- T2 cells (ATCC ® CRL-1992TM) (5e4) resuspended in TexMacs media are mixed 1:1 with individual viral peptides (50uM) to a final volume of lOOuL. After 10 minutes of incubation (37°C, 5% C02), T2 cells are incubated overnight at room temperature (14 hours). Cells are then incubated 2 hours at 37°C, 5% CO2, and stained with an anti-HLA A2 antibody (clone BB7.2, FITC labeled, BD Bioscience 551285, 20ug/mL). FITC Median of fluorescence is quantified to measure the capacity of each peptide to bind and stabilize the expression of FILA-A2 molecule on T2 cell surface.
- pan-coronavirus vaccine To evaluate immunogenicity of Pan-coronavirus vaccine, immunization experiments is to be conducted with escalating dose of the pan-coronavirus vaccine (5, 10, 25 or 50 ug of each peptide) after subcutaneous injection. Single versus repeated injection is to be tested (Day 0 only or Day 0 and Day 14) to evaluate prime/boost vaccination strategy to generate CD8 specific T cells.
- HLA-A2+ transgenic mice is used FILA-A/FI2-D 2Enge/J (Janvier Lab), or FILA-A2/DR1+ double transgenic mice (Pajot et al, 2004), or HLA-A2/H2kB transgenic mice (CB6Fl-Tg(HLA-A*0201/H2-Kb)A*0201; Taconic stock #9659).
- mice are sacrificed on Day 14 (Single vaccination) or Day 21 (Double vaccination) and CD8 T cells from spleen, lymph nodes, Lung or Bronchoalveolar lavages are isolated and their reactivity against optimized pan coronavirus peptides or wild type peptides are evaluated using IFNg Elispot assay. Briefly, CD8- T cells are pulsed with wild type or optimized peptides, then cocultured with CD8+ T cells. Reactivity against wild type and optimized peptide allows to confirm cross reactivity of CD8 T cells to wild type peptides and consequently protection against pan coronavirus sequence. IFNg positive spots are revealed and quantified 24 hours following CD8+: pulsed CD8- Tcells.
- CD8 T cells immunogenicity is to be measured using granzyme B Elispot assay to quantify cytolytic capacity of pan coronavirus specific T cells elicited by vaccination. Individual peptides stimulation versus a pool of peptide stimulation is done to assess T cell reactivity against each peptide.
- T cell phenotype is to be evaluated by flow cytometry to evaluated phenotype of viral specific CD8 T cells.
- viral peptide loaded Dextramer/Tetramer is to be used to analyze quantity of viral specific T cells after vaccination and their resident memory phenotype (CD103, CD49a, CXCR6, CXCR3).
- Cytotoxic activity of CD8 +T Cells obtained after pan coronavirus peptide mouse vaccination is to be measured by Chromium 51 release assay against HLA-A2 human cells presenting viral proteins.
- HLA-A2+ T2 human cells are pulsed overnight with the wild- type or optimized peptides and used as target cells to measure cytotoxic functions of elicited CD8+ T cells after vaccination.
- CD8 T cells isolated from immunized mice are expanded in vitro with peptide vaccine (2pg/mL each) plus cytokine (IL-7, IL-21 and IL-2) to increase the pool of viral-specific T cells.
- Peptide pulsed T2 cells or unpulsed T2 cells are labeled with chromium 51 then cocultured with CD8 T cells at ratio 40:1 or 15:1 for 4 hours. Chromium released by target T2 cells is quantified in the supernatant using a gamma counter to quantify specific cytolysis and normalized to negative control (spontaneous release, T2 cells without CD8 T cells) and maximum control (T2 cells lysed with Saponin).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a vaccine composition suitable for preventing or treating an infection by a coronavirus, said vaccine being adapted to provide a protection against several betacoronaviruses and optionally alphacoronaviruses.
Description
PAN-CORONAVIRUS PEPTIDE VACCINE
FIELD OF THE INVENTION
The present invention relates to the field of the medicine, especially of virology. More particularly, it relates to a vaccine against coronavirus.
BACKGROUND OF THE INVENTION
Betacoronaviruses have become of the greatest clinical importance as illustrated by COVID-19 pandemic caused by SARS-CoV-2. All viruses, including SARS-CoV-2, evolve over time and variants of the original virus appear. Thus, a vaccine designed to target the original virus could be less effective against some of the variants. Another issue is that SARS-CoV-2 is not the first Betacoronavirus that causes an epidemic. Indeed, SARS-CoV-1 was responsible of an epidemic in 2003 and the MERS-CoV was responsible of an epidemic in 2012. It is likely that other Betacoronaviruses emerge in the future. Therefore, one problem to solve is to provide a vaccine as universal as possible so as to be effective against the new variants or coronaviruses that could emerge.
Betacoronavirus includes four subgenera or lineages (A, B, C and D). OC43 and HKU1 cause the common cold and belong to lineage A; SARS-CoV-1 causing SARS and SARS-CoV-2 causing COVID-19 belong to lineage B and MERS-CoV causing MERS belongs to lineage C. Until now, epidemic and pandemic were caused by Betacoronaviruses. However, Alphacoronaviruses 229E and NL63 also cause common cold. Therefore, a vaccine against all human coronaviruses, either alpha or beta, could be advantageous.
SUMMARY AND DESCRIPTION OF THE INVENTION
Vaccines against coronavirus often target spike (S) proteins, sometimes the Nucleocapsid (N) proteins, which are both exposed at the surface of the virus. However, there is no predicted conserved T-cell epitope in the Spike or Nucleocapsid proteins capable to cover at least 3 out of the 5 human Betacoronaviruses. Contrary to the teaching of prior art focusing on spike as a priority target known as a key entry of the virus into the cells, the inventors had an approach based on mid and long term resistance against variants of the virus, instead of main action and/or recognition mechanism (mainly spike, nucleocapsid, membrane, envelope proteins) and concluded notably that the Spike, Nucleocapsid and Envelopetargets are not appropriate for a long-term and broad Betacoronavirus protection based on T- cell immunity.
After complex analysis of conservative epitopes, they identified 22 T-cell epitopes well conserved among the human Betacoronaviruses. 21 of them are located in the ORFlab replicase polyprotein and only one in the Membrane protein (see Tables 1 and 2). More specifically, 10 T cell epitopes have been identified as having 100 % homology with at least 4 out of the 5 human betacoronaviruses (SARS-CoV-1, SARS-CoV-
2, MERS-CoV, HCoV-OC43 and HCoV-HKUl) (see Table 1). Among these 10 epitopes, 6T-cell epitopes have been identified as having 100% homology with the 5 human betacoronaviruses and one of them (namely ab0o\/#1 SEQ ID NO: 1) is of particular interest because it presents 100 % homology with the two alpha and the five beta coronaviruses (betacoronaviruses SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV- OC43 and HCoV-HKUl; alphacoronaviruses 229E and NL63). 12 additional T cell epitopes with a single mismatch in the HLA-binding anchorage site and covering at least 4 out of 5 human betacoronaviruses have been identified. In addition, the inventors designed neo-epitopes (mutated epitopes) of some of these T cell epitopes (see Table 3) by substituting some amino acids in HLA-binding anchorage site to improve HLA affinity, hence immunogenicity and or world HLA coverage. Another advantage of the identified epitopes is that the epitopes have been selected also based on a large word HLA coverage ranging from 40 to 100 % in order not to be restricted to few HLA genotypes in the face of the difficulty of high HLA polymorphism in human.
The epitopes will be recognized by CD8 T cells through the interaction with HLA class I system. The activated CD8 T cells convert into Lymphocytes cytotoxic T cells (effector CTL) by the help of helper T Lymphocytes (HTL). The activated T cells are notably CD8 memory T cells allowing the long-term action of the vaccine.
Therefore, the inventors identified T cell epitopes suitable for preparing a multi-epitopes vaccine being adapted to provide a protection against several betacoronaviruses and optionally alphacoronaviruses. According to our knowledge, it is the first time that the identification of T cell epitopes is focused on this capacity to provide a broad protection among the betacoronaviruses.
Table 1: 10 T cell epitopes with 100 % homology with at least 4 out of the 5 human betacoronaviruses
Table 2: 12 T-cell epitopes covering at least 4 out of 5 human betacoronaviruses with a single mismatch in the HLA-binding
Table 3: neoepitope of some T-cell epitopes of Tables 1 and 2
The epitopes of Tables 1-3 are stable among the SARS-Cov-2clades, and none of them are mutated in the 15 variants of SARS-Cov-2 described to this date (B.l.1.7 (Alpha), B.1.351 (Beta), P.l (Gamma), B.1.427 /429 (Epsilon), B.l.617.1 (Kappa), B.l.617.2 (Delta), A.23.1, B.1.526 (lota), C.37, B.1.525 (Eta), P.3 (Theta), B.1.1.519, B.1.619, B.1.620, B.1.621).
Accordingly, the present invention relates to a vaccine composition comprising at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 2, 5-10 and 12-32. Optionally, the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, 4 and 11 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs 24, 25 and 28.
Optionally, the present invention relates to a vaccine composition comprising at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 5-10 and 13-32. Optionally, the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-4 and 11-12 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs 24, 25 and 28.
Alternatively, the present invention further relates to a vaccine composition comprising a nucleic acid or a set of nucleic acids encoding at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-32. Optionally, the nucleic acid or set of nucleic acids encodes at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2, 5-10 and 12-32. Optionally,
the nucleic acid or set of nucleic acids further encodes at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, 4 and 11.
The vaccine composition has the following advantages:
- it is pan-betacoronaviruses, optionally pan-alpha and betacoronaviruses;
- the anti-viral mechanism of action is cellular and long-term, especially T cell memory CTL (Cytotoxic T Lymphocytes); and
- it is suitable not only for HLA-A2 positive subjects but also HLA-A2 negative subjects.
Optionally, the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2, 5-10 and 12-32 or nucleic acid or set of nucleic acids encoding such at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitope. Optionally, the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, 4 and 11 or nucleic acid or set of nucleic acids encoding such at least one CTL epitope. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23 and 26 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. Optionally, the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, and 4 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 24 and 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. In a particular aspect, the vaccine composition further comprises an epitope of SEQ ID NO: 1 or a neoepitope of the epitope of SEQ ID NO: 1 such as the neoepitope of SEQ ID NO: 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 12-22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 29-32 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. Optionally, the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NO: 11 or a neoepitope thereof such as the neoepitopes of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or
between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitopes selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23 and 26 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. Optionally, the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, and 4 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 24 and 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. In a particular aspect, the vaccine composition further comprises an epitope of SEQ ID NO: 1 or a neoepitope of the epitope of SEQ ID NO: 1 such as the neoepitope of SEQ ID NO: 25 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL (neo)epitopes selected from the group consisting of epitopes of SEQ ID NOs: 12-22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 29-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes. Optionally, the vaccine composition may further comprise at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NO: 11 or a neoepitope thereof such as the neoepitopes of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 23-32 or nucleic acid or set of nucleic acids encoding such at least one CTL (neo)epitope. In a particular aspect, the vaccine composition comprises the neoepitope of SEQ ID NO: 25 or nucleic acid or set of nucleic acids encoding it. Optionally, the vaccine composition comprises at least 1, 2, 3, 4, 5, 6, 7 or 8 CTL neoepitopes selected from the group consisting of neoepitopes of SEQ ID NOs: 23-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitope. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-22 and at least one CTL neoepitope selected from the group consisting of
neoepitopes of SEQ ID NOs: 23-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes. Optionally, the vaccine composition comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-10 and at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 23-27 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes. Optionally, the vaccine composition comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 11-22 and at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 28-32 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 1-10, 12-27 and 29-31 and the CTL epitope of SEQ ID NO: 11 or a neoepitope thereof such as the CTL neoepitope of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding such CTL (neo)epitopes. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes and 1 or 2 of them are the CTL epitope of SEQ ID NO: 11 or a neoepitope thereof such as the CTL neoepitope of SEQ ID NO: 28 or nucleic acid or set of nucleic acids encoding them.
Optionally, the vaccine composition comprises at least 5, 6, 7 or 8 CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-32 or nucleic acid or set of nucleic acids encoding them. Optionally, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes or between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
In a particular aspect, the vaccine composition comprises between 5 and 15 CTL (neo)epitopes as disclosed above, especially between 6 and 14 CTL (neo)epitopes or between 7 and 13 CTL (neo)epitopes or between 8 and 12 CTL (neo)epitopes or nucleic acid or set of nucleic acids encoding them.
Optionally, the composition further comprises at least 1 HTL (Helper T Lymphocytes) peptide/epitope or a T helper peptide or nucleic acid or set of nucleic acids encoding it. The HTL epitopes are either natural or synthetic T cells helper peptides know in the art. Natural helper peptides are for instance a Natural Tetanus sequence alone or linked to another epitope, or a Plasmodium falciparum sequence alone or linked to another epitope. In a particular aspect, the HTL peptide may comprise a synthetic peptide such as a Pan-DR-binding epitope (e.g., a PADRE® peptide, Epimmune Inc., San Diego, CA, described, for example, in U.S. Patent Number 5,736,142), for example, having the sequence (aKXVAAWTLKAAa with X and a respectively indicating cyclohexylalanine and d-alanine) (SEQ ID NO: 33). Certain pan-DR binding
epitopes comprise all "L" natural amino acid residues; these molecules can be provided as peptides or in the form of nucleic acids that encode the peptide. See also, U.S. Patent Numbers 5,679,640 and 6,413,935.
Optionally, the vaccine composition may further comprise an adjuvant. The adjuvant is preferably an oily adjuvant, which comprises both a hydrocarbon oil and a water-in-oil emulsifier. Such adjuvants act by the so-called "deposition effect". The hydrocarbon oil may be paraffin oil, a vegetable oil, squalene, squalane or mineral oil, for instance. Suitable W/O emulsifiers may be selected from mannide mono-oleate and sorbitan mono-oleate, for instance. Examples of appropriate oily adjuvants are a mixture of mineral oil and mannide mono-oleate, more particularly a mixture of 5-20% mannide mono-oleate with 80-95% mineral oil (Montanide® ISA 51 sold by SEPPIC) or squalene (Montanide® ISA 720 sold by SEPPIC) and similar mixtures. In a specific embodiment, the adjuvant is a mixture of mineral oil and mannide mono- oleate, especially Montanide® ISA 51.
In a particular aspect, the vaccine composition is an emulsion with a mineral oil adjuvant.
The adjuvant used in this invention may alternatively, or in addition to the above oily adjuvants, be selected from micro- and nanoparticles, such as liposomes and microspheres, of PLG, PLA, PLGA or other natural polymers such as gelatin, collagen and chitosan. Other adjuvants may comprise TLR ligands, Toll like receptor ligands (TLR3 and TLR9), stimulators of IFN genes (STING) agonists, cytokines such as GM- CSF and IL2, carbohydrates, bacterial derivatives, mineral salts and immune stimulating complexes (ISCOM).
Optionally, the vaccine composition may comprise aluminum salts, such as aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate.
The vaccine composition may further comprise one or more "pharmaceutically acceptable carriers". These are typically large, slowly metabolized macromolecules such as proteins, saccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose (Paoletti, 2001, Vaccine, 19:2118-2126), trehalose (WO 00/56365), lactose and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. In some aspect, the vaccine compositions contain diluents, such as water, saline, glycerol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. Sterile pyrogen-free, phosphate buffered physiologic saline is a typical carrier (Gennaro, 2000, Remington: The Science and Practice of Pharmacy, 20th edition, ISBN:0683306472).
The vaccine compositions are intended for parenteral, topical, oral, intrathecal, or local administration. Preferably, the vaccine compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. More preferably, the vaccine composition is intended for subcutaneous
administration or intramuscular administration. Optionally, the vaccine composition is intended for nasal administration.
Optionally, each peptide or (neo)epitope of the composition is present at a concentration of 0.01 mg/ml to 1 g/ml, 0.1 mg/ml to 10 mg/ml. For instance, each peptide can be present at a concentration of 0.5 mg/ml.
Optionally, the vaccine composition comprises the CTL (neo)epitopes, each at a dose of between 1 and 100 pg, preferably between 5 and 50 pg. It may comprise the T helper peptide, especially PADRE, at a dose of between 1 and 100 pg, preferably between 5 and 50 pg.
Optionally, the total number of epitope peptides in the composition can be from 1 to 40, from 2 to 30 or from 3 to 20 peptides. Optionally, the vaccine composition may further comprise other peptides than disclosed in the present invention. For instance, the other peptides may be non-exhaustively selected among the T cell epitopes disclosed in Syed Faraz Ahmed et al (Viruses, 12, 254, 2020), W02004/110349, W02004/092360, Grifoni et al (Cell Host and Microbe, 27, 671, 2020).
Optionally, the T cell epitopes can be included in a larger peptide of less than 15, 20, 30, 40 or 50 amino acids in length. Optionally, the T cell epitopes can be in the form of a polypeptide in which several T cell epitopes are fused. Optionally, the T cell epitopes can be in the form of a carrier such as a nanoparticle bearing said T cell epitopes. Optionally, instead of the T cell epitope, the vaccine composition may include a nucleic acid encoding said T cell epitopes.
The vaccine composition may comprise a nucleic acid or a set of nucleic acids encoding the CTL (neo)epitopes as disclosed herein.
Nucleic acids of the vaccine can be or can include deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a b-D-ribo configuration, a-LNA having an a-L-ribo configuration (a diastereomer of LNA), 2'-amino-LNA having a 2'-amino functionalization, and 2'-amino- a-LNA having a 2'- amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA) and/or chimeras and/or combinations thereof.
In a particular aspect, the nucleic acid or set of nucleic acids of the vaccine composition is a mRNA polynucleotide or a set of mRNA polynucleotides. The technology of mRNA vaccine is now well-known by the person skilled in the art. For illustrating this aspect, see WO21159130, the the disclosure thereof being incorporated herein by reference. The composition may comprise one nucleic acid for each (neo)epitope of the vaccine or nucleic acid encoding several of the (neo)epitopes or all of the (neo)epitopes.
mRNA polynucleotides can contain stabilizing elements, including, but not limited to untranslated regions (UTR) at their 5 '-end (5' UTR) and/or at their 3'-end (3' UTR), in addition to other structural features, such as a 5'-cap structure or a 3'-poly(A) tail. Preferably, mRNA polynucleotides comprise at least one modification and at least one 5' terminal cap.
5 '-capping of polynucleotides may be completed concomitantly during the in vitro- transcription reaction using the following chemical RNA cap analogs to generate the 5'-guanosine cap structure according to manufacturer protocols: 3'-0-Me-m7G(5')ppp(5') G [the ARC A cap];G(5')ppp(5')A; G(5')ppp(5')G; m7G(5')ppp(5')A; m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA). 5 '-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the "Cap 0" structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA). Cap 1 structure may be generated using both Vaccinia Vims Capping Enzyme and a 2'-0 methyl-transferase to generate: m7G(5')ppp(5')G-2'-0- methyl. Cap 2 structure may be generated from the Cap 1 structure followed by the 2'-0-methylation of the 5 '-antepenultimate nucleotide using a 2'-0 methyl- transferase. Cap 3 structure may be generated from the Cap 2 structure followed by the 2'-0- methylation of the 5'-preantepenultimate nucleotide using a 2'-0 methyl-transferase. Enzymes may be derived from a recombinant source.
The mRNA polynucleotides may comprise modified nucleotides and nucleosides. Non-limiting examples of such non-naturally occurring modified nucleotides and nucleosides can be found, inter alia, in published US application Nos. PCT/US2012/058519; PCT/US2013/075177; PCT/US2014/058897;
PCT/US2014/058891; PCT/US2014/070413; PCT/US2015/36773; PCT/US2015/36759;
PCT/US2015/36771; or PCT/IB2017/051367 all of which are incorporated by reference herein. More specifically, modified nucleobases in nucleic acids (e.g., mRNA) may comprise 1- methyl-pseudouridine (itiΐy), 1 -ethyl-pseudouridine (eli[>), 5-methoxy-uridine (mo5U), 5- methyl-cytidine (m5C), and/or pseudouridine (y). Other examples of modified nucleobases include 5- methoxymethyl uridine, 5- methylthio uridine, 1-methoxymethyl pseudouridine, 5-methyl cytidine, and/or 5-methoxy cytidine. The polyribonucleotide may include a combination of at least two (e.g., 2, 3, 4 or more) of any of the aforementioned modified nucleobases. More specifically, the mRNA may comprise 1 -methyl- pseudouridine (itiΐy) substitutions at one or more or all uridine positions of the nucleic acid. Alternatively, the mRNA may comprise 1 -methyl-pseudouridine (itiΐy) substitutions at one or more or all uridine positions of the nucleic acid and 5-methyl cytidine substitutions at one or more or all cytidine positions of the nucleic acid. In another alternative, the mRNA may comprise pseudouridine (y) substitutions at one or more or all uridine positions of the nucleic acid and optionally 5-methyl cytidine substitutions at one or more or all cytidine positions of the nucleic acid.
The 3'-poly(A) tail is typically a stretch of adenine nucleotides added to the 3 '-end of the transcribed mRNA. It can, in some instances, comprise up to about 400 adenine nucleotides.
Optionally, the mRNA polynucleotide or set of mRNA polynucleotides is/are formulated in at least one lipid nanoparticle, especially a lipid nanoparticle comprising a mixture of lipids. Lipid nanoparticles typically comprise ionizable cationic lipid, non-cationic lipid, sterol and PEG lipid components along with the nucleic acid cargo of interest. The lipid nanoparticles of the disclosure can be generated using components, compositions, and methods as are generally known in the art, see for example PCT/US2016/052352; PCT/US2016/068300; PCT/US2017/037551; PCT/US2015/027400;
PCT/US2016/047406; PCT/US2016/000129; PCT/US2016/014280; PCT/US2016/014280;
PCT/US2017/038426; PCT/US2014/027077; PCT/US2014/055394; PCT/US2016/52117;
PCT/US2012/069610; PCT/US2017/027492; PCT/US2016/059575 and PCT/US2016/069491 all of which are incorporated by reference herein in their entirety.
In a particular aspect, the lipid nanoparticle comprises at least one ionizable cationic lipid, at least one non-cationic lipid/neutral lipid, at least one sterol, and/or at least one polyethylene glycol (PEG)-modified lipid. For instance, the non-cationic lipid can be 1,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), 1,2- dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), l,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1.2-dimyristoyl-sn-gly cero- phosphocholine (DMPC), l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1.2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), l,2-di-0-octadecenyl-sn-glycero-3- phosphocholine (18:0 Diether PC), l-oleoyl-2 cholesterylhemisuccinoyl-sn-glycero-3- phosphocholine (OChemsPC), l-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2- dilinolenoyl-sn-glycero-3- phosphocholine,l,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2- didocosahexaenoyl-sn-glycero-3- phosphocholine, l,2-diphytanoyl-sn-glycero-3- phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn- glycero-3-phosphoethanolamine, 1,2- dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl- sn-glycero-3- phosphoethanolamine, l,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2- didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l,2-dioleoyl-sn-glycero-3-phospho-rac- (1- glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof. The PEG modified lipid can be a PEG- modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG- modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof. In some embodiments, the PEG-modified lipid is DMG-PEG, PEG-c- DOMG (also referred to as PEG-DOMG), PEG-DSG and/or PEG-DPG. The sterol can be cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha- tocopherol, and mixtures thereof.
In a specific aspect, the lipid mixture comprises heptadecan-9-yl 8 ((2 hydroxy ethyl) (6 oxo 6- (undecyloxy)hexyl)amino)octanoate as ionizable cationic lipid, 1,2 distearoyl sn glycero-3 phosphocholine (DSPC) as neutral lipid, cholesterol as sterol and 1- monomethoxypolyethyleneglycol-2,3-
dimyristylglycerol with polyethylene glycol of average molecular weight 2000 (PEG2000 DMG) as PEG- modified lipid.
Optionally, the vaccine composition may comprise an 25 pg to 250 pg dose of mRNA encoding a (neo)epitope. Optimally, the vaccine composition may further include a pharmaceutically-acceptable excipient, inert or active. The excipient in the pharmaceutical composition must be "acceptable" also in the sense that it is compatible with mRNA and can be capable of stabilizing it. One or more excipients (e.g., solubilizing agents) can be utilized as pharmaceutical carriers for delivery of the mRNA. Examples of a pharmaceutically acceptable excipients include, but are not limited to, biocompatible vehicles (e.g., LNPs), carriers, adjuvants, additives, and diluents to achieve a composition usable as a dosage form. Examples of other excipients include colloidal silicon oxide, magnesium stearate, cellulose, and sodium lauryl sulfate. Additional suitable pharmaceutical excipients, as well as pharmaceutical necessities for their use, are described in Remington's Pharmaceutical Sciences. Optionally, the vaccine composition does not include an adjuvant.
The vaccine compositions are intended for parenteral, topical, oral, intrathecal, or local administration. Preferably, the vaccine compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. More preferably, the vaccine composition is intended for subcutaneous administration or intramuscular administration. Optionally, the vaccine composition is intended for nasal administration.
In a particular aspect, the vaccine composition is to be administered once, twice or more. For instance, two administrations can be carried out. A prime administration followed by a boost administration. For instance, the injections can be spaced by 3 weeks or 2 weeks and will be adapted to the Immune response requested and to the medical conditions of the subject to be treated.
The present invention relates to a vaccine composition as disclosed herein for use for preventing or treating an infection by a coronavirus; the use of a vaccine composition as disclosed herein for the manufacture of a vaccine for preventing or treating an infection by a coronavirus; and to a method for preventing or treating an infection by a coronavirus in a subject, comprising the administration of an effective amount of a vaccine composition as disclosed herein.
Optionally, the coronavirus is an alphacoronavirus or a betacoronavirus, preferably a betacoronavirus. More specifically, the vaccine composition is suitable for preventing or treating an infection by several betacoronaviruses. Optionally, the vaccine composition is suitable for preventing or treating an infection by an alphacoronavirus.
In one aspect, the vaccine composition as disclosed herein is for use for preventing or treating an infection by an alphacoronavirus and a betacoronavirus. In this aspect, the vaccine composition comprises the epitope of SEQ ID NO: 1 or a neoepitope thereof such as the neoepitope of SEQ ID NO: 25.
Optionally, the betacoronavirus is selected from the group consisting of SARS-CoV-1, SARS-CoV-2, MERS- CoV, HCoV-OC43 and HCoV-HKUl, more specifically the group consisting of SARS-CoV-1, SARS-CoV-2, and MERS-CoV. More specifically, the vaccine composition as disclosed herein is for use for preventing or treating an infection by SARS-CoV-1, SARS-CoV-2, and MERS-CoV, optionally by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-OC43 and HCoV-HKUl.
Optionally, the subject to be treated is a subject aged 65 years or older, a subject having a cancer or having had a cancer, a subject being obese (In particular with severe obesity (body mass index [BMI] of 40 or higher [CDC- HCSP BMI >30]), a subject being diabetic, a subject having a hypertension, a subject having a sarcoidosis, a subject being immunocompromised, a subject who lives in a nursing home or long-term care facility, a subject with chronic lung disease or moderate to severe asthma, lung fibrosis, a subject who has serious heart conditions, a subject with chronic kidney disease undergoing dialysis and/or a subject with liver diseases; and/or a subject being HLA-A2. Many conditions can cause a person to be immunocompromised (including cancer treatment, smoking, bone marrow or organ transplantation, immune deficiencies, poorly controlled HIV or AIDS, prolonged use of corticosteroids and other immune weakening medications).
The patient could be selected on HLA typing. In a very specific aspect, the subject is HLA-A2.
Definitions
A "diluent" includes sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred diluent for pharmaceutical compositions. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as diluents, particularly for injectable solutions.
An "epitope" is the collective features of a molecule, such as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an immunoglobulin, T cell receptor or HLA molecule. Alternatively, an epitope can be defined as a set of amino acid residues which is involved in recognition by a particular immunoglobulin, or in the context of T cells, those residues necessary for recognition by T cell receptor proteins and/or Major Histocompatibility Complex (MHC) receptors. It is referred as "T cell epitope" and "CTL epitope". Epitopes are present in nature, and can be isolated, purified or otherwise prepared or derived by humans. For example, epitopes can be prepared by isolation from a natural source, or they can be synthesized in accordance with standard protocols in the art. Synthetic epitopes can comprise artificial amino acid residues, "amino acid mimetics," such as D isomers of
naturally-occurring L amino acid residues or non-naturally-occurring amino acid residues such as cyclohexylalanine. Throughout this disclosure, epitopes may be referred to in some cases as peptides or peptide epitopes.
"Human Leukocyte Antigen" or"HLA" is a human class I or class II Major Histocompatibility Complex (MHC) protein (see, e.g., Stites, et al., IMMUNOLOGY, 8TH ED., Lange Publishing, Los Altos, CA (1994).
An "HLA supertype or HLA family", as used herein, describes sets of HLA molecules grouped on the basis of shared peptide-binding specificities. HLA class I molecules that share somewhat similar binding affinity for peptides bearing certain amino acid motifs are grouped into such HLA supertypes. The terms HLA superfamily, HLA supertype family, HLA family, and HLAxx-like molecules (where "xx" denotes a particular HLA type), are synonyms.
"Major Histocompatibility Complex" or "MHC" is a cluster of genes that plays a role in control of the cellular interactions responsible for physiologic immune responses. In humans, the MHC complex is also known as the human leukocyte antigen (HLA) complex. For a detailed description of the MHC and HLA complexes, see, Paul, FUNDAMENTAL IMMUNOLOGY, 3RD ED., Raven Press, New York (1993).
A "native" or a "wild type" sequence refers to a sequence found in nature. Such a sequence may comprise a longer sequence in nature.
The terms "peptide", "epitope" and "peptide epitope" are used interchangeably with "oligopeptide" in the present specification to designate a series of residues, typically L-amino acid residues, connected one to the other, typically by peptide bonds between the a-amino and carboxyl groups of adjacent amino acid residues.
Optionally, a "peptide", "epitope" and "peptide epitope" defined by a SEQ ID NO can consist in the particular SEQ ID NO and can also refer to a peptide consisting in the particular SEQ ID NO but including 1 or 2 additional amino acids at the N and/or C terminal end of the SEQ ID NO.
Optionally, one or several "peptide", "epitope" and "peptide epitope" can be fused together in a same polypeptide.
A "neoepitope" is a peptide or an epitope comprising one or two substitutions of an amino acid aiming to improve the HLA binding, in particular the binding by HLA-A2. In particular, the neoepitope only includes on substitution. In a very particular aspect, the substituted amino acid is the C-terminal amino acid of the T cell epitope.
A "PanDR binding" peptide, a "PanDR binding epitope," or "PADRE®" peptide (Epimmune, San Diego, CA) is a member of a family of molecules that binds more than one HLA class II DR molecule. The pattern that defines the PADRE® family of molecules can be referred to as an HLA Class II supermotif. A PADRE®
molecule binds to HLA-DR molecules and stimulates in vitro and in vivo human helper T lymphocyte (HTL) responses. For a further definition of the PADRE® family, see copending application U.S. serial Nos. 09/709,774, filed November 11, 2000; and 09/707,738, filed November 6, 2000; PCT publication Nos WO 95/07707, and WO 97/26784; U.S. Patent Nos. 5,736,142 issued April 7, 1998; 5,679,640, issued October 21, 1997; and 6,413,935, issued July 2, 2002.
"Pharmaceutically acceptable" refers to a generally non-toxic, inert, and/or physiologically compatible composition or component of a composition.
A "pharmaceutical excipient" or "excipient" comprises a material such as an adjuvant, a carrier, pH- adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like. A "pharmaceutical excipient" is an excipient which is pharmaceutically acceptable.
As used herein, the term "infection by a coronavirus" designates any infection or disease caused by the coronavirus.
A "protective immune response" or "therapeutic immune response" refers to a CTL and/or an HTL response to an antigen derived from a pathogenic antigen (e.g., an antigen from an infectious agent or a tumor antigen), which in some way prevents or at least partially arrests disease symptoms, side effects or progression. The immune response may also include an antibody response which has been facilitated by the stimulation of helper T cells.
As used herein, a "vaccine" is a composition used for vaccination, e.g., for prophylaxis or therapy, that comprises one or more peptides of the invention. There are numerous embodiments of vaccines in accordance with the invention, such as by a cocktail of one or more peptides; one or more peptides of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The "one or more peptides" can include any whole unit integer from 1-32, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32 peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class l-binding peptides of the invention can be linked or to otherwise be combined with HLA class II- binding peptides, e.g., a PADRE® universal HTL-binding peptide, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. Vaccines can comprise peptide pulsed antigen presenting cells, e.g., dendritic cells.
EXAMPLES
Binding and stability of peptides to HLA-A2 molecules.
The binding and stability of pan coronavirus peptides to HLA expressed on the cell surface is to be measured using a T2 binding assay wild type peptides and optimized peptides will be compared. 174CEM.T2 is a human lymphoma-derived cell line expressing a low level of HLA-A2 on the cell surface due to TAP deficiency (TAP = transporter associated with antigen presentation), and can only present exogenous peptides. Binding of exogenous peptides to HLA-A2 stabilizes the HLA-A2/peptide complexes on the cell surface which can be detected using immunofluorescence staining. T2 cells (ATCC® CRL-1992™) (5e4) resuspended in TexMacs media are mixed 1:1 with individual viral peptides (50uM) to a final volume of lOOuL. After 10 minutes of incubation (37°C, 5% C02), T2 cells are incubated overnight at room temperature (14 hours). Cells are then incubated 2 hours at 37°C, 5% CO2, and stained with an anti-HLA A2 antibody (clone BB7.2, FITC labeled, BD Bioscience 551285, 20ug/mL). FITC Median of fluorescence is quantified to measure the capacity of each peptide to bind and stabilize the expression of FILA-A2 molecule on T2 cell surface.
Immunogenicity evaluation of Pan-coronavirus vaccine
To evaluate immunogenicity of Pan-coronavirus vaccine, immunization experiments is to be conducted with escalating dose of the pan-coronavirus vaccine (5, 10, 25 or 50 ug of each peptide) after subcutaneous injection. Single versus repeated injection is to be tested (Day 0 only or Day 0 and Day 14) to evaluate prime/boost vaccination strategy to generate CD8 specific T cells. For this study, human HLA- A2+ transgenic mice is used FILA-A/FI2-D 2Enge/J (Janvier Lab), or FILA-A2/DR1+ double transgenic mice (Pajot et al, 2004), or HLA-A2/H2kB transgenic mice (CB6Fl-Tg(HLA-A*0201/H2-Kb)A*0201; Taconic stock #9659). After immunization, mice are sacrificed on Day 14 (Single vaccination) or Day 21 (Double vaccination) and CD8 T cells from spleen, lymph nodes, Lung or Bronchoalveolar lavages are isolated and their reactivity against optimized pan coronavirus peptides or wild type peptides are evaluated using IFNg Elispot assay. Briefly, CD8- T cells are pulsed with wild type or optimized peptides, then cocultured with CD8+ T cells. Reactivity against wild type and optimized peptide allows to confirm cross reactivity of CD8 T cells to wild type peptides and consequently protection against pan coronavirus sequence. IFNg positive spots are revealed and quantified 24 hours following CD8+: pulsed CD8- Tcells. Similarly, CD8 T cells immunogenicity is to be measured using granzyme B Elispot assay to quantify cytolytic capacity of pan coronavirus specific T cells elicited by vaccination. Individual peptides stimulation versus a pool of peptide stimulation is done to assess T cell reactivity against each peptide.
In parallel, T cell phenotype is to be evaluated by flow cytometry to evaluated phenotype of viral specific CD8 T cells. For this purpose, viral peptide loaded Dextramer/Tetramer is to be used to analyze quantity
of viral specific T cells after vaccination and their resident memory phenotype (CD103, CD49a, CXCR6, CXCR3).
Cytotoxic activity of viral specific elicited CD8 T cells after in vivo vaccination
Cytotoxic activity of CD8 +T Cells obtained after pan coronavirus peptide mouse vaccination is to be measured by Chromium 51 release assay against HLA-A2 human cells presenting viral proteins. To mimic viral peptides presentation by HLA-A2 cells, HLA-A2+ T2 human cells are pulsed overnight with the wild- type or optimized peptides and used as target cells to measure cytotoxic functions of elicited CD8+ T cells after vaccination. Prior the assay, CD8 T cells isolated from immunized mice are expanded in vitro with peptide vaccine (2pg/mL each) plus cytokine (IL-7, IL-21 and IL-2) to increase the pool of viral-specific T cells. Peptide pulsed T2 cells or unpulsed T2 cells are labeled with chromium 51 then cocultured with CD8 T cells at ratio 40:1 or 15:1 for 4 hours. Chromium released by target T2 cells is quantified in the supernatant using a gamma counter to quantify specific cytolysis and normalized to negative control (spontaneous release, T2 cells without CD8 T cells) and maximum control (T2 cells lysed with Saponin).
Claims
Claims
1- A vaccine composition comprising at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 5-10 and 13-32.
2- The vaccine composition of claim 1, wherein the vaccine composition further comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-4 and 11-12.
3- The vaccine composition of any one of claims 1-2, wherein the vaccine composition comprises a CTL epitope of SEQ ID NO: 1 or a neoepitope thereof such as the neoepitope of SEQ ID NO: 25.
4- The vaccine composition of any one of claims 1-2, wherein the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23-27.
5- The vaccine composition of any one of claims 1-2, wherein the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 12-22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 28-32.
6- The vaccine composition of any one of claims 1-2, wherein the vaccine composition comprises at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 23-32, preferably at least the CTL neoepitope of SEQ ID NO: 25.
7- The vaccine composition of claim 6, wherein the vaccine composition further comprises at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-22.
8- The vaccine composition of claim 2, wherein the vaccine composition comprises at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 1-10, 12-27 and 29-31 and the CTL epitope of SEQ ID NO: 11 or a neoepitope thereof such as the CTL neoepitope of SEQ ID NO: 28.
9- The vaccine composition of any one of claims 1-9, wherein the vaccine composition further comprises a T helper peptide, especially PADRE (aKXVAAWTLKAAa with X and a respectively indicating cyclohexylalanine and d-alanine).
10- The vaccine composition of any one of claims 1-9, wherein the vaccine composition further comprises an adjuvant.
11- The vaccine composition of claim 10, wherein the adjuvant is a mixture of mineral oil and mannide mono-oleate, especially Montanide® ISA 51.
12- A vaccine comprising a nucleic acid or a set of nucleic acids encoding at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-32.
13- The vaccine of claim 12, wherein the nucleic acid or set of nucleic acids encodes at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2, 5-10 and 12-32.
14- The vaccine of claim 13, wherein the nucleic acid or set of nucleic acids further encodes at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1, 3, 4 and 11.
15- The vaccine composition of any one of claims 12-14, wherein the nucleic acid or set of nucleic acids encodes a CTL epitope of SEQ ID NO: 1 or a neoepitope thereof such as the neoepitope of SEQ ID NO: 25.
16- The vaccine composition of any one of claims 12-14, wherein the nucleic acid or set of nucleic acids encodes at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 2 and 5-10 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 23-27.
17- The vaccine composition of any one of claims 12-14, wherein the nucleic acid or set of nucleic acids encodes at least one CTL (neo)epitope selected from the group consisting of epitopes of SEQ ID NOs: 12- 22 or a neoepitope thereof such as the neoepitopes of SEQ ID NOs: 28-32.
18- The vaccine composition of any one of claims 12-14, wherein the nucleic acid or set of nucleic acids encodes at least one CTL neoepitope selected from the group consisting of neoepitopes of SEQ ID NOs: 23-32, preferably at least the CTL neoepitope of SEQ ID NO: 25.
19- The vaccine composition of claim 18, wherein the nucleic acid or set of nucleic acids encodes at least one CTL epitope selected from the group consisting of epitopes of SEQ ID NOs: 1-22.
20- The vaccine composition of claim 12 or 13, wherein the nucleic acid or set of nucleic acids encodes at least one CTL (neo)epitope selected from the group consisting of (neo)epitopes of SEQ ID NOs: 1-10, 12- 27 and 29-31 and the CTL epitope of SEQ ID NO: 11 or a neoepitope thereof such as the CTL neoepitope of SEQ ID NO: 28.
21- The vaccine composition of any one of claims 12-20, wherein the nucleic acid or set of nucleic acids encodes a T helper peptide.
22- The vaccine composition of any one of claims 12-21, wherein the nucleic acid or set of nucleic acids is a mRNA polynucleotide or a set of mRNA polynucleotides.
23- The vaccine composition of claim 22, wherein the vaccine has one or several of the following features: the mRNA polynucleotide or set of mRNA polynucleotides is/are formulated in at least one lipid nanoparticle, especially a lipid nanoparticle comprising a mixture of lipids comprising: an ionizable amino lipid such as heptadecan-9-yl 8 ((2 hydroxyethyl)(6 oxo 6-
(undecyloxy)hexyl)amino)octanoate; cholesterol; l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); and 1,2 dimyristoyl-sn-glycerol, methoxypolyethyleneglycol (DMG-PEG); and/or
the mRNA polynucleotide or set of mRNA polynucleotides comprise(s) a chemical modification selected from Nl-methyl-pseudouridine or Nl-ethyl-pseudouridine; and/or the mRNA polynucleotide or set of mRNA polynucleotides comprise(s) a chemical modification in the carbon-5 position of the uracil; and/or - the mRNA polynucleotide or set of mRNA polynucleotides comprise(s) at least one 5' terminal cap, 7mG(5')ppp(5')NlmpNp.
24- A vaccine composition of any one of claims 1-23, for use for preventing or treating an infection by a betacoronavirus.
25- The vaccine composition for use of claim 24, wherein the betacoronavirus is selected from the group consisting of SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-OC43 and HCoV-HKUl, more specifically the group consisting of SARS-CoV-1, SARS-CoV-2, and MERS-CoV.
26- The vaccine composition for use of claim 24, wherein the vaccine composition is for use for preventing or treating an infection by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-OC43 and HCoV-HKUl, preferably by SARS-CoV, SARS-CoV-2, and MERS-CoV. 27- The vaccine composition for use of any one of claims 24-26, wherein the vaccine composition comprises a CTL epitope of SEQ ID NO: 1 or a neoepitope thereof such as the neoepitope of SEQ ID NO: 25 or a nucleic acid encoding it and the vaccine composition is further for use for preventing or treating an infection by an alphacoronavirus, more specifically the group consisting of alphacoronaviruses 229E and NL63. 28- A method of preventing or treating an infection by a betacoronavirus in a subject; the method comprising: administering to the subject a therapeutically effective amount of a vaccine composition according to any one of claims 1-23, wherein the composition elicits an immune response in the subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21305866.2 | 2021-06-23 | ||
EP21305866 | 2021-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022268916A2 true WO2022268916A2 (en) | 2022-12-29 |
WO2022268916A3 WO2022268916A3 (en) | 2023-03-02 |
Family
ID=77042856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/067082 WO2022268916A2 (en) | 2021-06-23 | 2022-06-23 | Pan-coronavirus peptide vaccine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022268916A2 (en) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007707A1 (en) | 1993-09-14 | 1995-03-23 | Cytel Corporation | Alteration of immune response using pan dr-binding peptides |
WO1997026784A1 (en) | 1996-01-24 | 1997-07-31 | Cytel Corporation | Induction of immune response against desired determinants |
US5679640A (en) | 1991-02-12 | 1997-10-21 | Cytel Corporation | Immunosuppressant peptides |
WO2000056365A1 (en) | 1999-03-23 | 2000-09-28 | Aventis Pasteur | Use of trehalose for stabilising a liquid vaccine |
US6413935B1 (en) | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
WO2004092360A2 (en) | 2003-04-10 | 2004-10-28 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
WO2004110349A2 (en) | 2003-05-14 | 2004-12-23 | Siga Technologies, Inc. | Sars t cell epitopes and methods for identifying same |
US20150036773A1 (en) | 2010-04-01 | 2015-02-05 | Ismail Lakkis | Cancellation System for Millimeter-Wave Radar |
US20150036771A1 (en) | 2012-04-20 | 2015-02-05 | Huawei Technologies Co., Ltd. | Device and method for communication correction |
US20150036759A1 (en) | 2013-08-03 | 2015-02-05 | Gregory Hubert Piesinger | COFDM Using Pseudo Orthogonal QPSK Coding |
US20160052117A1 (en) | 2014-08-25 | 2016-02-25 | Daniel D. Cougar | Roofing and nail removal hammer |
US9707738B1 (en) | 2016-01-14 | 2017-07-18 | Chang Chun Petrochemical Co., Ltd. | Copper foil and methods of use |
US9709774B2 (en) | 2011-10-21 | 2017-07-18 | Samsung Electro-Mechanics Co., Ltd. | Imaging lens |
WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160235837A1 (en) * | 2013-10-16 | 2016-08-18 | Samuel Bogoch | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV) |
WO2021163398A1 (en) * | 2020-02-14 | 2021-08-19 | Epivax, Inc. | T cell epitope clusters and related compositions useful in the prevention, diagnosis, and treatment of covid-19 |
EP4121104A2 (en) * | 2020-03-20 | 2023-01-25 | BioNTech SE | Coronavirus vaccines and methods of use |
CN116056722A (en) * | 2020-04-20 | 2023-05-02 | Nec奥克尔姆内特公司 | SARS-COV-2 vaccine |
EP4153730A1 (en) * | 2020-05-19 | 2023-03-29 | Gritstone bio, Inc. | Sars-cov-2 vaccines |
WO2022011160A2 (en) * | 2020-07-08 | 2022-01-13 | The Brigham And Women's Hospital, Inc. | Severe acute respiratory syndrome coronavirus 2 (sars cov-2) peptide epitopes |
WO2022148455A1 (en) * | 2021-01-11 | 2022-07-14 | The Hong Kong University Of Science And Technology | Identification and uses of peptide sequences of sars-cov-2 t cell and b cell epitopes |
WO2022159511A2 (en) * | 2021-01-19 | 2022-07-28 | Gritstone Bio, Inc. | Modified alphavirus vectors |
-
2022
- 2022-06-23 WO PCT/EP2022/067082 patent/WO2022268916A2/en unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679640A (en) | 1991-02-12 | 1997-10-21 | Cytel Corporation | Immunosuppressant peptides |
WO1995007707A1 (en) | 1993-09-14 | 1995-03-23 | Cytel Corporation | Alteration of immune response using pan dr-binding peptides |
US5736142A (en) | 1993-09-14 | 1998-04-07 | Cytel Corporation | Alteration of immune response using pan DR-binding peptides |
US6413935B1 (en) | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
WO1997026784A1 (en) | 1996-01-24 | 1997-07-31 | Cytel Corporation | Induction of immune response against desired determinants |
WO2000056365A1 (en) | 1999-03-23 | 2000-09-28 | Aventis Pasteur | Use of trehalose for stabilising a liquid vaccine |
WO2004092360A2 (en) | 2003-04-10 | 2004-10-28 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
WO2004110349A2 (en) | 2003-05-14 | 2004-12-23 | Siga Technologies, Inc. | Sars t cell epitopes and methods for identifying same |
US20150036773A1 (en) | 2010-04-01 | 2015-02-05 | Ismail Lakkis | Cancellation System for Millimeter-Wave Radar |
US9709774B2 (en) | 2011-10-21 | 2017-07-18 | Samsung Electro-Mechanics Co., Ltd. | Imaging lens |
US20150036771A1 (en) | 2012-04-20 | 2015-02-05 | Huawei Technologies Co., Ltd. | Device and method for communication correction |
US20150036759A1 (en) | 2013-08-03 | 2015-02-05 | Gregory Hubert Piesinger | COFDM Using Pseudo Orthogonal QPSK Coding |
US20160052117A1 (en) | 2014-08-25 | 2016-02-25 | Daniel D. Cougar | Roofing and nail removal hammer |
US9707738B1 (en) | 2016-01-14 | 2017-07-18 | Chang Chun Petrochemical Co., Ltd. | Copper foil and methods of use |
WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
Non-Patent Citations (6)
Title |
---|
GENNARO: "Remington: The Science and Practice of Pharmacy", 2000 |
GRIFONI ET AL., CELL HOST AND MICROBE, vol. 27, 2020, pages 671 |
PAOLETTI, VACCINE, vol. 19, 2001, pages 2118 - 2126 |
PAUL: "FUNDAMENTAL IMMUNOLOGY", 1993, RAVEN PRESS |
STITES ET AL.: "IMMUNOLOGY", 1994, LANGE PUBLISHING |
SYED FARAZ AHMED ET AL., VIRUSES, vol. 12, 2020, pages 254 |
Also Published As
Publication number | Publication date |
---|---|
WO2022268916A3 (en) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220347292A1 (en) | Human cytomegalovirus vaccine | |
JP7096282B2 (en) | RNA preparation for immunotherapy | |
JP2022017499A (en) | Therapeutic anticancer neoepitope vaccine | |
CN109310739A (en) | Neoantigen and its application method | |
KR20180004820A (en) | A novel prime-boost therapy comprising administration of at least one mRNA construct | |
CN104736553A (en) | Cell penetrating peptides | |
CN104840953A (en) | Composition for treating prostate cancer (PCa) | |
US20210283242A1 (en) | Immune-mediated coronavirus treatments | |
US20070298051A1 (en) | Adjuvants Of Immune Response | |
SA519410007B1 (en) | Peptides and methods for the treatment of diabetes | |
CN112867502A (en) | HERV-K derived antigens as consensus tumor antigens for use in anti-cancer vaccines | |
KR102190180B1 (en) | Dna vaccine | |
WO2004044155A2 (en) | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE | |
KR20220010500A (en) | RNA for the treatment of ovarian cancer | |
KR20210138586A (en) | RNA for the treatment of prostate cancer | |
JP2014508762A (en) | Combination cell based gp96-Ig-SIV / HIV, recombinant gp120 protein vaccination for protection against SIV / HIV | |
TW201938793A (en) | A novel vaccine adjuvant | |
RU2555345C2 (en) | Treatment of choroidal neovascularisation by means of vaccines | |
Pascolo | Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history | |
US20140199347A1 (en) | Adjuvant compositions with 4-1bbl | |
WO2022268916A2 (en) | Pan-coronavirus peptide vaccine | |
TW202035446A (en) | Combination therapy with neoantigen vaccine | |
US20230181726A1 (en) | A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide | |
RU2773273C2 (en) | Neoantigens and their application methods | |
WO2023220645A1 (en) | Vaccine for human t-lymphotropic virus-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22736237 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |